INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA
DOI:
https://doi.org/10.15407/exp-oncology.2024.03.253Keywords:
head and neck squamous cell carcinoma, radiation therapy, COX-2 inhibitor, cisplatin, vascular endothelial growth factor, cyclooxygenase-2, prostaglandin E-2Abstract
Background. The development of new approaches to modeling tumor radiosensitivity in patients with head and neck squamous cell carcinoma (HNSCC) is an important problem for overcoming tumor radioresistance. New agents for radiomodification are inhibitors of the enzyme cyclooxygenase-2 (COX-2). The study of markers of radioresistance in cancer patients undergoing radiotherapy (RT) in combination with COX-2 inhibitors and chemotherapy may contribute to the effectiveness of RT. Aim. To determine the effect of conformal RT in combination with radiomodifiers (celecoxib, cisplatin, or their combination) on the content of vascular endothelial growth factor (VEGF), COX-2, and prostaglandin E-2 (PGE-2) in the serum of patients with HNSCC. Materials and Methods. 47 patients with HNSCC were divided into 4 groups: RT in combination with celecoxib and cisplatin, RT with cisplatin, RT with celecoxib, and RT. Patients received radiation treatment on a Clinac 600C linear accelerator. The levels of VEGF, COX-2, and PGE-2 in the serum were determined by enzyme immunoassay. Results. Blocking COX-2 in patients with HNSCC leads to a decrease in VEGF levels. The largest decrease in VEGF levels was observed in a group treated by RT in combination with celecoxib and cisplatin, indicating a more effective antiangiogenic effect. The changes in the levels of VEGF, COX-2, and PGE-2, which are most pronounced under the combined effect of RT and both radiomodifiers, coincided with an objective response to radiation treatment. Conclusions. The data obtained indicate the effect of radiomodification on the suppression of angiogenesis, which is most pronounced under the combined effect of RT and both radiomodifiers. The decrease in the levels of PGE- 2, COX-2, and VEGF coincides with the clinical efficacy of radiotherapy according to RECIST 1.1 criteria.
References
Fedorenko ZP, Gulak LO, Gorokh EL, et al. Cancer in Ukraine, 20202021. Incidence, mortality, performance indi cators of the oncology service. Bull Nat Cancer Reg Ukraine, 2022. Accessed from: http://www.ncru.inf.ua/publica tions/BULL_24/index_e.htm
Kim DY, Wu HG, Kim JH, et al. Radiotherapy versus surgery in earlystage HPVpositive oropharyngeal cancer.
Cancer Res Treat. 2022;54(2):406416. https://doi.org/10.4143/crt.2021.441
Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase2 inhibitors in the management of tumor an giogenesis. Prog Exp Tumor Res. 2003;37:179192. https://doi.org/10.1159/000071373. PMID: 12795055.
Mitryaeva N, Starenkyi V, Bilozor N, et al. Radiosensitization with Cyclooxygenase-2 Inhibitors in Radiation Therapy of Malignant Tumors. Kharkiv: IMRO, 2021. 136 p. ISBN 9789669663382 (in Ukrainian).
Mitryaeva NA, Grebinik LV, Uzlenkova NE. Effect of combined action of Xradiation and COX2 inhibitor meloxivet on the content of VEGF and PGE2 in the blood serum of tumorbearing rats. Probl Rad Med Radiobiol. 2019;24;261 269. https://doi.org/10.33145/23048336201924231269
Chiang KH, Shieh JM, Shen CJ, et al. Epidermal growth factorinduced COX2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietinlike. Cancer Sci. 2020;111(6):20042015. https://doi. org/10.1111/cas.14400
Yokouchi H, Kanazawa K. Revisiting the role of COX2 inhibitor for nonsmall cell lung cancer. Transl Lung Cancer Res. 2015;4(5): 660664. https://doi.org/10.3978/j.issn.22186751.2015.04.03
Santoro A, Bufo P, Russo G, et al. Expression and clinical implication of cyclooxygenase2 and Ecadherin in oral squamous cell carcinomas Cancer Biol Ther. 20202;(8):667674. https://doi.org/10.1080/15384047.2015.1071741
Xu L, Stevens J, Hilton M, et al. COX2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med. 201425;6(242):242ra84. https://doi.org/10.1126/scitranslmed.3008455
Cheki M, Yahyapour R, Farhood B, et al. COX2 in radiotherapy: a potential target for radioprotection and radiosen sitization. Curr Mol Pharmacol. 2018;11(3):173183. https://doi.org/10.2174/1874467211666180219102520
Han Z, Liao H, Shi F, et al. Inhibition of cyclooxygenase2 sensitizes lung cancer cells to radiationinduced apoptosis.
Oncol Lett. 2017;14(5):59595965. https://doi.org/10.3892/ol.2017.6940
Laube M, Kniess T, Pietzsch J. Development of antioxidant COX2 inhibitors as radioprotective agents for radiation therapy—a hypothesisdriven review. Antioxidants. 2016;5(2):14. https://doi.org/10.3390/antiox5020014
Peltanova B, Liskova M, Gumulec J, et al. Sensitivity to cisplatin in head and neck cancer cells is signifi antly affected by patientderived cancerassociated fibroblasts. Int J Mol Sci. 2021;22(4):1912. https://doi.org/10.3390/ijms22041912
Head and Neck Cancers / NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) // Version 4.2024 — May 1, 2024. www.nccn.org/patients
Ang K, Zhang Q, Rosenthal D, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma. J Clin Oncol. 2014;32(27):29402950. https:// doi.org/10.1200/JCO.2013.53.5633
Li S, Jiang M, Wang L, Yu S. Combined chemotherapy with cyclooxygenase2 (COX2) inhibitors in treating human cancers: Recent advancement. Biomed Pharmacother. 2020;129:110389. https://doi.org/10.1016/j.biopha.2020.110389
Lundin E, Reizenstein J, Landstrom F, et al. Radiotherapy a selective treatment of the nodenegative neck in oral squamous cell cancer. Anticancer Res. 2021;41(7):34893498. https://doi.org/10.21873/anticanres.15136.
Bilozor N, Artyukh S, Mitryaeva N, et al. The content of VEGF, COX2, PGE2 in the blood serum of patients with PCa in the dynamics of conformal radiation therapy. Ukr Radiol J. 2018;26(2):9398 (in Ukrainian).
Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem. 2019;88:102925. https://doi.org/10.1016/j. bioorg.2019.102925
Zhang CC, Li CG, Wang YF, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase3/GSDME activation. Apoptosis. 2019;24(34):312325. https://doi.org/10.1007/s10495 019015151
Sofia Vala I, Martins LR, Imaizumi N, et al. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One. 2010;5(6):e11222. https://doi.org/10.1371/journal.pone.0011222
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Experimental Oncology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.